Lynce, Filipa http://orcid.org/0000-0001-6615-7076
Williams, James T.
Regan, Meredith M.
Bunnell, Craig A.
Freedman, Rachel A.
Tolaney, Sara M.
Chen, Wendy Y.
Mayer, Erica L.
Partridge, Ann H.
Winer, Eric P.
Overmoyer, Beth
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
https://doi.org/10.1007/s00280-021-04245-x
Funding for this research was provided by:
Incyte Corporation
Article History
Received: 18 November 2020
Accepted: 5 February 2021
First Online: 14 February 2021
Compliance with ethical standards
:
: FL has received research grants from Pfizer, Immunomedics, Regeneron, Chugai, Tesaro, Calithera, Inivata and BMS and has participated on advisory boards from Pfizer (remunerated) and BMS, Astra Zeneca and Jounce (non remunerated). BO has received clinical trial support from Incyte, Eisai. SMT receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. RAF receives institutional funding from Eisai and Puma Biotechnology. ELM has served as a consultant/advisor to Novartis, Lilly, Sanofi, and Eisai. MMR reports research funding from Novartis, Pfizer, Ipsen, TerSera, Merck, Pierre Fabre, Roche, AstraZeneca, Bristol Myers Squibb, Bayer, Veridex; and consulting or advisory role for Ipsen, Bristol-Myers Squibb, Tolmar Pharmaceuticals.
: This study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DFCI#13–494; NCT02041429).
: Informed consent was obtained from all subjects.
: Not applicable.